TNFRSF17 and Miyoshi myopathy: To move forward, dual targeting approaches against BCMA and GPRC5D on the surface of MM cells, may depict the most promising strategy to overcome sBCMA abundance and antigen escape, as demonstrated by an interim update of a phase-1 study (NCT05652335), testing JNJ-5322 as the first-in-class BCMA×GPRC5D×CD3 trispecific antibody in triple-class exposed MM.